Drug Development

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

From AI-powered diagnostics to non-hallucinogenic psychedelics, 2025's discoveries are redefining mental healthcare and offering new hope.

A biotech firm's promising concussion therapy, backed by NFL's Alex Smith, shows an 85% responder rate and now seeks public funding for its final push.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

A promising antiviral combination for Long COVID gets a major boost, accelerating its path to a pivotal clinical trial led by top researchers.

With major clinical trials, including a novel approach for Alzheimer's, and key market access wins, MMI's Symani system is poised to redefine microsurgery.

Processa Pharmaceuticals completes enrollment for a pivotal analysis of its NGC-Cap therapy, offering new hope for a safer, more effective cancer treatment.

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

Weight Watchers now offers the new Wegovy pill, a needle-free option, betting its future on combining powerful GLP-1 drugs with its classic support.

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.

NorthStar Medical Radioisotopes will showcase its revolutionary cancer-fighting isotopes, Ac-225 and Cu-67, at the prestigious J.P. Morgan conference.

A new once-monthly, self-injected cholesterol drug gets FDA nod, offering more convenience and setting the stage for a major market push in China.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Astellas Pharma's new deal with venture studio Autobahn Labs isn't just a partnership; it's a strategic overhaul of the R&D pipeline. Here's why.

A tech-driven 'anti-CRO' and a clinical accelerator have joined forces. Can their integrated model finally fix the broken drug development pipeline?

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.